Women and Testosterone Therapy

Women naturally produce testosterone (from ovaries and adrenals) at about 10% of male levels. It's essential for libido, energy, muscle maintenance, bone density, and cognitive function. Testosterone declines with age, especially after menopause or surgical ovary removal. Approved indications (varies by country): hypoactive sexual desire disorder (HSDD) — the only FDA-adjacent indication, post-surgical menopause with persistent low libido despite adequate estrogen therapy, and premature ovarian insufficiency. Off-label but clinically common: persistent fatigue, low mood, and decreased well-being in menopausal women with low measured testosterone. Unlike men, there is no FDA-approved testosterone product for women in the US — all prescribing is off-label or compounded.

Female testosterone dosing is 1/10th to 1/20th of male doses. Typical female TRT: compounded testosterone cream 0.5-2mg/day, injectable testosterone 5-15mg/week (compare to male 100-200mg), testosterone pellets 50-100mg every 3-4 months (male: 600-1200mg), and transdermal patch (no longer available in US but was 300mcg/day). The therapeutic window is narrow — too much causes virilization (deepening voice, facial hair, clitoral enlargement). Monitoring is critical: aim for testosterone levels in the upper-normal female range (30-70 ng/dL, compared to male 300-1000 ng/dL). Labs must use sensitive assays (LC-MS/MS) because standard immunoassays are unreliable at female levels.

Virilization — development of male characteristics — is the primary concern with female testosterone therapy. Androgenic side effects: hirsutism (facial/body hair growth), deepening of the voice (often permanent — the most feared side effect), clitoromegaly (clitoral enlargement, usually reversible with dose reduction), male-pattern hair loss (scalp), and acne. These are dose-dependent and largely reversible if caught early, except voice deepening which can be permanent. Regular monitoring of total and free testosterone, SHBG, and clinical examination for signs of virilization is essential. Women should be counseled on what to watch for and told to report any voice changes immediately. Most women on appropriate, monitored doses do not experience significant virilization.

There is no FDA-approved testosterone product for women in the United States. The Intrinsa patch was withdrawn. In Australia, testosterone cream is approved for female HSDD. In the UK, off-label prescribing is common through specialist menopause clinics. This creates a dangerous situation: women desperate for help seek out online clinics, compounding pharmacies, or even black-market male preparations dosed inappropriately. Pellet clinics have emerged as a common source — convenient but with fixed, non-adjustable dosing. The lack of approved products means women must be especially careful about provider selection and compounded product quality. A knowledgeable menopause specialist or reproductive endocrinologist is ideal, but access is limited.